Abstract: The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include deoxygenated hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs.

Abstract: Disclosed are monomeric avidin-like proteins with a strong and stable biotin-binding ability, protein conjugates containing two or more of the monomeric avidin-like proteins and having a multivalent binding ability to biotin, nucleic acid molecules for encoding the monomeric avidin-like proteins, and methods for producing the monomeric avidin-like proteins, so the monomeric avidin-like proteins, due to the monomeric structure, are free from a problem of the disruption of receptor functions, caused by oligomerization occurring in existing tetrameric streptavidin or tetrameric but monovalent streptavidin variants.

Abstract: Method for increasing the shelf-life of a pharmaceutical composition comprising a glucagon-like peptide which is prepared from a peptide product that has been dried at a pH above neutral pH.

Abstract: The invention relates to the transdermal application of oligopeptides for reducing synaptic transmission in tissues of an animal. In one aspect, this invention relates to compositions comprising an oligopeptide and optionally a carrier comprising a positively charged “backbone” having positively charged branching or “efficiency” groups, as described herein. Most preferably the positively charged carrier is a long-chain positively charged polypeptide or a positively charged nonpeptidyl polymer, for example, a polyalkyleneimine. The invention further relates methods for producing a biologic effect of reducing synaptic transmission in a tissue by topically applying an effective amount of such a composition, preferably to the skin, of a subject or patient in need of such treatment.

Abstract: Expression systems are disclosed for the direct expression of peptide products into the culture media where genetically engineered host cells are grown. High yield was achieved with novel vectors, a special selection of hosts, and/or fermentation processes which include careful control of cell growth rate, and use of an inducer during growth phase. Special vectors are provided which include control regions having multiple promoters linked operably with coding regions encoding a signal peptide upstream from a coding region encoding the peptide of interest. Multiple transcription cassettes are also used to increase yield. The production of amidated peptides using the expression systems is also disclosed.

Abstract: The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV.

Abstract: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed.

Abstract: A long-acting improver of muscular fatigue characterized by comprising 4 kinds of amino acids made up of leucine, isoleucine, valine and glutamine, and a whey protein component (whey protein and/or decomposition product of whey protein). At least one of a whey protein isolate (WPI), a whey protein concentrate (WPC), ?-lactoglobulin, and ?-lactalbumin is used as the whey protein. Novel food or drink, and pharmaceuticals which exhibit sustained recovery effects on muscular fatigue are provided.

Abstract: The invention relates to proton-translocating retinal proteins which exhibit a photocycle which is retarded as compared with the wild type and whose all-trans retinal contents in the light-adapted and dark-adapted states do not differ from each other by more than 10%. The invention furthermore relates to a photochromic composition and to the use of the proton-translocating retinal proteins and the photochromic composition.

Abstract: La present invention pertains to a composition of plasma-derived virally-safe factor VIII, obtained after nanometric filtration, said composition comprising von Willebrand factor (vWF) at a rate of 15% or less of decamers and higher multimers. Such compositions have a reduction factor of the virus titre higher than 4 log and are thus suitable for treatment of hemophilia.

Abstract: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building materials that are susceptible to such infestation are also disclosed.

Abstract: The present invention is directed to a powder delivery system containing a composition comprising gelatin or collagen powder having a mean particle size of at least 10 ?m. The gelatin or collagen powder is typically in dry form, i.e. no liquid components and/or propellants are added to the composition. The present invention is also directed to an improved powder delivery system which contains a protective structure, such as a skirt, located close to the orifice of the delivery system. In a further aspect, the present invention is directed to gelatin- or collagen-based compositions useful in hemostatic applications. In a further aspect of the invention the powder delivery system comprises gelatin or collagen powder in a dry form ready to use. Further the powder delivery system in a dry form might comprise an agent incompatible with moisture and/or water.

Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.

Abstract: To provide a method of arranging ferritin by which a high rate of the number of the molecular film spots on which sole ferritin molecule was arranged in effect, with respect to total number of the molecular film spots provided for arranging ferritin (sole arrangement rate) is achieved is objected to. Specifically, in Fer8 ferritin having a sequence excluding 7 amino acids of from the second to the eighth, from an amino acid sequence (Fer0 sequence) translated from a naturally occurring DNA sequence, lysine at position 91 is substituted with glutamic acid.

Abstract: A protein body derivable from Fabaceae has a reversible, anisotropic contractability such that the protein body becomes thicker perpendicular to a longitudinal axis of the protein body and shorter along the longitudinal axis of the protein body when increasing a calcium ion concentration in a medium surrounding the protein body past a threshold value of 30 nM. The protein body becomes thinner perpendicular to the longitudinal axis and longer along the longitudinal axis when decreasing the calcium ion concentration below the threshold value of 30 nM. Also, the protein body becomes thicker in the direction perpendicular to the longitudinal axis when increasing a pH value of a medium surrounding the protein body to a value above 9.5 without becoming shorter along the longitudinal axis. The protein body becomes thinner in the direction perpendicular to the longitudinal axis without becoming longer decreasing the pH value below 9.5.

Abstract: A method for renaturation of proteins comprising adding to a solution of denatured, chemically modified or reduced proteins a refolding buffer containing a primary, secondary or tertiary amine. Said method has been applied, for example, to interleukin-4 and bovine pancreatic trypsin inhibitor (BPTI), which were previously (i) solubilized in the presence of guanidinium hydrochloride as chaotronic agent, and (ii) subjected to sulfitolysis.

Abstract: The invention provides a biocompatible material derived from keratin that is useful for many aspects of medical treatment of bone. The keratin material is preferably S-sulfonated and enriched in intermediate filament proteins of high molecular weight. The keratin material may be porous for use as a bone replacement and augmentation product but also provided is the use of dense keratin materials in bone treatment for use as an internal fixation appliance in the treatment of bone fractures and bone regeneration, and a method for preparing the keratin material for use in the preservation, restoration and development of form and function of bone.

Abstract: A composition comprising an albumin-based colloid composition having at least one protected thiol region, method of making the same, and method for use, including treating hypovolemic conditions such as capillary leak syndrome and shock, are disclosed.

Abstract: A peptide including a first peptide sequence of formula KLAKLAK (SEQ ID NO:11)in which K is lysine, L is leucine and A is alanine, and a second peptide sequence of formula (B) in which B is a peptide of 4 to 15 amino acids positively charged at neutral pH, including at least one peptide motif of formula ?xx? (SEQ ID NO:13)in which ? is a basic amino acid and X is any amino acid, and in which the first peptide sequence is repeated n times and the second peptide sequence is repeated m times, n and m being whole numbers between 1 and 5.

Abstract: The invention relates to a method for separating fibronectin from plasma fractions by adjusting a pH value of less than 5.4 such that fibronectin is precipitated and extracted from the solution.